



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, August 13, 2019

J.B. Chemicals reports robust Q1 growth

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its consolidated unaudited financial results for the quarter ended on June 30, 2019. The highlight of Y-o-Y results is as under:

Consolidated Financial Performance:

Particulars	Q1		YoY Growth (%)
	2019-20	2018-19	
Sales	435.09	398.75	9.11
Other Operating income	11.02	8.16	35.05
Other Income	12.61	1.42	788.03
Total Income	458.72	408.33	12.34
Operating Profit (EBIT)	80.18	66.13	21.25
EBITDA	95.98	80.82	18.76
Profit before tax	91.99	66.26	38.83
Profit after tax	62.11	45.76	35.73
EPS (Rs.) (FV 2)	7.73	5.46	

Sales Performance:

Sales	Q1		YoY Growth (%)
	2019-20	2018-19	
Domestic Formulations	206.67	174.48	18.45
Formulations exports	148.39	140.98	5.26
API Business	18.91	20.76	(8.91)
Subsidiary Sales	55.71	58.25	(4.36)
Other Sales/Income	5.41	4.28	26.40
Total Sales	435.09	398.75	9.11

- Sales growth was led by 19.5% growth in domestic formulations business. Calcium channel blocker products sales significantly contributed the growth. Chronic segment products sales were 44% of the total sales.

- EBIDTA of 22% for the quarter against 20.27% in the corresponding period in the previous year. The higher profitability was a result of favourable product mix and cost optimization.
- The increase in other income was mainly on account of higher mark-to-market gain due to spike in the bond yield during the quarter.
- Domestic Formulations sales at Rs. 192.91 crores registered growth of 19.5%, while domestic sales of contrast media products at Rs. 13.76 crores were 5.6% higher.
- Formulations exports in Global Business (other than Russia-CIS) at Rs.107.74 crores registered growth of 6.2%, while exports to Russia-CIS market at Rs. 34.16 crores registered growth of 19.82%.
- Sales by Company's South African subsidiary at Rs. 38.69 crores were lower by 9.5% due to lower private market sales and exports.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its State-of-the-Art manufacturing facilities are approved by health authorities of important regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary and Vice President- Compliance
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2439 5311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.